We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls
Read MoreHide Full Article
Key Takeaways
Bio-Rad reported Q3 adjusted EPS of $2.26, missing estimates but rising 11.9% year over year.
BIO's revenues grew 0.5% to $653 million, surpassing expectations on Life Science and Diagnostics sales.
BIO's gross margin contracted 219 bps, while operating profit rose 1.2% and operating margin hit 10%.
Bio-Rad Laboratories, Inc. (BIO - Free Report) posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from the prior-year quarter’s level.
The quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.
The company’s GAAP loss was $12.70 per share compared to the EPS of $23.34 a year ago.
BIO's Q3 Revenues
Revenues of $653 million topped the Zacks Consensus Estimate by 0.24%. The figure also edged up 0.5% year over year (down 1.7% at constant exchange rate or CER).
Following the earnings announcement, Bio-Rad shares dropped 2.96% in yesterday’s after-market trading.
BIO's Segmental Analysis
Sales in the Life Science segment totaled $261.8 million, up 0.3% year over year (down 1.5% at CER). The currency-neutral year-over-year sales decline was due to a constrained academic research and biotech funding environment.
Bio-Rad Laboratories, Inc. Price, Consensus and EPS Surprise
Net sales in the Clinical Diagnostics segment were $391.2 million, up 0.6% on a year-over-year basis (down 1.8% at CER). The currency-neutral year-over-year sales decrease was primarily due to lower reimbursement rates for diabetes testing in China.
BIO’s Margin Performance
In the quarter under review, Bio-Rad’s gross profit declined 3.5% to $343.4 million. The gross margin contracted 219 basis points (bps) to 52.6%.
Operating expenses amounted to $278.1 million, down 4.6% year over year. The operating profit totaled $65.3 million, up 1.2% from the prior-year level. The operating margin expanded 7 bps to 10%.
BIO's Financial Update
Bio-Rad exited the third quarter of 2025 with cash and cash equivalents (including short-term investments) of $1.42 billion compared with $1.37 billion at the second-quarter end.
Total debt (including current maturities) at the end of 2024 was $1.20 billion, which remained flat on a sequential basis.
Net cash flow from operating activities totaled $367.3 million compared with the year-ago figure of $331 million.
Bio-Rad’s 2025 Guidance
Bio-Rad reiterated its financial guidance for full-year 2025, with adjusted, currency-neutral revenue growth of approximately 0-1%. The Zacks Consensus Estimate for the company’s revenues is pegged at $2.58 billion, implying a 0.6% increase from the 2024 reported figure.
The adjusted operating margin for the full year is projected to be between 12% and 13%.
Our Take on BIO
Bio-Rad exited the third quarter with earnings missing and revenues surpassing estimates. The company continued to navigate a dynamic global environment and evolving conditions across the markets for its life science and clinical diagnostics products. Research customers continue to face uncertainty and are cautious with their budgets, reflected through continued weak instrument demand and some softness in consumables. The contraction of the gross margin is also discouraging.
On a promising note, Bio-Rad advanced its Droplet Digital PCR strategy during the quarter. The process chromatography business in Life Science experienced strong double-digit growth due to the timing of customer orders. The company expects the Diagnostics segment to return to growth in the fourth quarter, with the China reimbursement headwind annualizing and revenues from the quality controls portfolio expected to be realized.
BIO’s Zacks Rank and Key Picks
Bio-Rad currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls
Key Takeaways
Bio-Rad Laboratories, Inc. (BIO - Free Report) posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from the prior-year quarter’s level.
The quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.
The company’s GAAP loss was $12.70 per share compared to the EPS of $23.34 a year ago.
BIO's Q3 Revenues
Revenues of $653 million topped the Zacks Consensus Estimate by 0.24%. The figure also edged up 0.5% year over year (down 1.7% at constant exchange rate or CER).
Following the earnings announcement, Bio-Rad shares dropped 2.96% in yesterday’s after-market trading.
BIO's Segmental Analysis
Sales in the Life Science segment totaled $261.8 million, up 0.3% year over year (down 1.5% at CER). The currency-neutral year-over-year sales decline was due to a constrained academic research and biotech funding environment.
Bio-Rad Laboratories, Inc. Price, Consensus and EPS Surprise
Bio-Rad Laboratories, Inc. price-consensus-eps-surprise-chart | Bio-Rad Laboratories, Inc. Quote
Net sales in the Clinical Diagnostics segment were $391.2 million, up 0.6% on a year-over-year basis (down 1.8% at CER). The currency-neutral year-over-year sales decrease was primarily due to lower reimbursement rates for diabetes testing in China.
BIO’s Margin Performance
In the quarter under review, Bio-Rad’s gross profit declined 3.5% to $343.4 million. The gross margin contracted 219 basis points (bps) to 52.6%.
Operating expenses amounted to $278.1 million, down 4.6% year over year. The operating profit totaled $65.3 million, up 1.2% from the prior-year level. The operating margin expanded 7 bps to 10%.
BIO's Financial Update
Bio-Rad exited the third quarter of 2025 with cash and cash equivalents (including short-term investments) of $1.42 billion compared with $1.37 billion at the second-quarter end.
Total debt (including current maturities) at the end of 2024 was $1.20 billion, which remained flat on a sequential basis.
Net cash flow from operating activities totaled $367.3 million compared with the year-ago figure of $331 million.
Bio-Rad’s 2025 Guidance
Bio-Rad reiterated its financial guidance for full-year 2025, with adjusted, currency-neutral revenue growth of approximately 0-1%. The Zacks Consensus Estimate for the company’s revenues is pegged at $2.58 billion, implying a 0.6% increase from the 2024 reported figure.
The adjusted operating margin for the full year is projected to be between 12% and 13%.
Our Take on BIO
Bio-Rad exited the third quarter with earnings missing and revenues surpassing estimates. The company continued to navigate a dynamic global environment and evolving conditions across the markets for its life science and clinical diagnostics products. Research customers continue to face uncertainty and are cautious with their budgets, reflected through continued weak instrument demand and some softness in consumables. The contraction of the gross margin is also discouraging.
On a promising note, Bio-Rad advanced its Droplet Digital PCR strategy during the quarter. The process chromatography business in Life Science experienced strong double-digit growth due to the timing of customer orders. The company expects the Diagnostics segment to return to growth in the fourth quarter, with the China reimbursement headwind annualizing and revenues from the quality controls portfolio expected to be realized.
BIO’s Zacks Rank and Key Picks
Bio-Rad currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.